Privium Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Privium Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.78M	Sell	39,944 -18,785	-32%	-$4.07M	1.8%	20
2026 Q1	$9.93M	Buy	58,729 +1,851	+3%	+$320K	2.07%	15
2025 Q4	$10.4M	Buy	56,878 +4,146	+8%	+$579K	1.91%	17
2025 Q3	$6.4M	Hold	52,732	–	–	1.15%	17
2025 Q2	$5.43M	Hold	52,732	–	–	1.17%	14
2025 Q1	$6.15M	Sell	52,732 -9,500	-15%	-$1.08M	1.6%	14
2024 Q4	$5.27M	Sell	62,232 -18,000	-22%	-$1.66M	1.19%	18
2024 Q3	$7.21M	Buy	80,232 +5,900	+8%	+$515K	1.79%	16
2024 Q2	$5.87M	Sell	74,332 -7,700	-9%	-$570K	1.5%	20
2024 Q1	$6.55M	Buy	82,032 +10,000	+14%	+$839K	1.75%	17
2023 Q4	$5.55M	Hold	72,032	–	–	1.55%	22
2023 Q3	$5.03M	Hold	72,032	–	–	1.5%	20
2023 Q2	$5.27M	Sell	72,032 -87,442	-55%	-$6.45M	1.52%	19
2023 Q1	$9.84M	Buy	+159,474	New	+$10.5M	3.3%	8

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Privium Fund Management's AXSM Position: Q2 2026 in Review

Privium Fund Management reduced its Axsome Therapeutics (AXSM) stake by 32% in Q2 2026, selling an estimated $4.07M and leaving 39,944 shares worth $9.78M. The position accounts for 1.8% of the portfolio, ranked #20.

Privium Fund Management first reported a position in AXSM in Q1 2023 and has held it in 14 quarters since. The position peaked at $10.4M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Privium Fund Management held 39,944 shares of Axsome Therapeutics worth $9.78M as of Q2 2026.
Privium Fund Management sold 18,785 Axsome Therapeutics shares in Q2 2026, an estimated $4.07M.
Axsome Therapeutics made up 1.8% of Privium Fund Management's portfolio in Q2 2026, its #20 holding.
Privium Fund Management first reported a position in Axsome Therapeutics in Q1 2023 and has held it in 14 quarters since.
Privium Fund Management's Axsome Therapeutics position peaked at $10.4M in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.